Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$26.91 USD
-0.26 (-0.96%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $26.91 0.00 (0.00%) 7:46 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 21 - 40 ( 195 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
FDA Accepts Ensifentrine New Drug Application for Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
New Drug Application Acceptance Imminent; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q2: NDA Acceptance in August; Near-Term Focus Remains on Launch Preparations
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine New Drug Application Submitted on Schedule; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
NDA Submitted for Ensifentrine/COPD; On-Track for Potential Approval in H1:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Pivotal Trial Expanded Analyses Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ENHANCE-ing Our Understanding of Ensifentrine with ATS Posters Mgmt Dinner
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ATS Presentations to Showcase Additional Ph3 ENHANCE Program Analyses; Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Regulatory Submission Preparations Ongoing; 1Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Phase 3 Trial in China Doses First Patient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R